The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Doctors at the All India Institute of Medical Sciences (AIIMS) in New Delhi have completed…
The Reserve Bank of India has cancelled Certificates of Registration (CoRs) of 49 NBFCs and…
Trust in Times of Crisis: The Story of a Citizens’ Relief Effort for the Pandemic…
The Indian Wholesale Price Index (WPI)-based inflation rate rise to the 12.29 percent in October…
Lala Lajpat Rai (Punjab Kesari) was a prominent freedom fighter, nationalist, writer and social reformer.…
The National Sports Board (NSB) got a fresh set of leaders on 16 th November…